Drug intelligence / Profile preview

WT-9361

Development stage: Preclinical
Lead developer: WARF Therapeutics
Modality: Small Molecules

Overview

WT-9361 is a small-molecule ligand developed by WARF Therapeutics that specifically targets prostate-specific membrane antigen (PSMA). PSMA is a cell-surface protein that is significantly upregulated in prostate cancer cells compared to normal tissues, making it a valuable target for precision medicine. WT-9361 is designed to bind with high affinity to PSMA, potentially serving as a delivery vehicle for imaging agents or therapeutic payloads. The program is currently in the lead optimization phase (Stage 4) of preclinical development for the treatment and management of prostate cancer.

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on WT-9361.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WT-9361.

Explore the full profile